Nkarta Inc

NASDAQ NKTX

Data sourced from

and

Download Data

Nkarta Inc Working Capital to Current Liabilities Ratio 2 year CAGR for the Trailing 12 Months (TTM) ending March 31, 2024: -7.78%

Nkarta Inc Working Capital to Current Liabilities Ratio 2 year CAGR is -7.78% for the Trailing 12 Months (TTM) ending March 31, 2024, a 49.43% change year over year. The working capital to current liabilities ratio measures the proportion of working capital to current liabilities. It is calculated by dividing the difference between current assets and current liabilities by current liabilities. This ratio indicates the company's ability to cover its current liabilities with its working capital. A higher ratio suggests a healthier liquidity position and better ability to meet short-term obligations. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Nkarta Inc Working Capital to Current Liabilities Ratio for the Trailing 12 Months (TTM) ending March 31, 2023 was 18.89, a -15.26% change year over year.
Nkarta Inc Working Capital to Current Liabilities Ratio for the Trailing 12 Months (TTM) ending March 31, 2022 was 22.29, a -15.53% change year over year.
Nkarta Inc Working Capital to Current Liabilities Ratio for the Trailing 12 Months (TTM) ending March 31, 2021 was 26.39, a 878.72% change year over year.
Nkarta Inc Working Capital to Current Liabilities Ratio for the Trailing 12 Months (TTM) ending March 31, 2020 was 2.70.

NASDAQ: NKTX

Nkarta Inc

CEO	Mr. Paul J. Hastings
IPO Date	July 10, 2020
Location	United States
Headquarters	6000 Shoreline Court, South San Francisco, CA, United States, 94080
Employees	150
Sector	Healthcare
Industry	Biotechnology

Description

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Key trends